Full Press Release Details
Pharmaceuticals to Present at the Leerink Partners Roundtable Series in
New York September 28, 2016
VICTORIA, British Columbia--(BUSINESS WIRE)--September 22, 2016--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH /TSX:AUP), a clinical stage
biopharmaceutical company focused on the global immunology market, today
announced that its Chief Executive Officer, Charles Rowland, will
participate in a Fireside Chat at the Leerink Partners Roundtable
Series: Rare Disease and Immuno-Oncology on September 28, 2016 at
11:05am ET in New York. To access the live webcast, please visit the
investor section of the Aurinia website. A replay will also be archived
on the site following the event.
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high unmet
medical need. The company is currently developing voclosporin, an
investigational drug, for the treatment of lupus nephritis (LN). The
company is headquartered in Victoria, BC and focuses its development
efforts globally. www.auriniapharma.com
Voclosporin, an investigational drug, is a novel and potentially
best-in-class calcineurin inhibitor ("CNI") with clinical data in over
2,000 patients in other indications. Voclosporin is an
immunosuppressant, with a synergistic and dual mechanism of action that
has the potential to improve near- and long-term outcomes in LN when
added to standard of care (MMF). By inhibiting calcineurin, voclosporin
blocks IL-2 expression and T-cell mediated immune responses. It is made
by a modification of a single amino acid of the cyclosporine molecule
which has shown a more predictable pharmacokinetic and pharmacodynamic
relationship, an increase in potency, an altered metabolic profile, and
potential for flat dosing. The Company anticipates that upon regulatory
approval, patent protection for voclosporin will be extended in the
United States and certain other major markets, including Europe and
Japan, until at least October 2027 under the Hatch-Waxman Act and
comparable laws in other countries.
About Lupus Nephritis (LN)
Lupus Nephritis (LN) in an inflammation of the kidney caused by Systemic
Lupus Erythematosus (SLE) and represents a serious progression of SLE.
SLE is a chronic, complex and often disabling disorder and affects more
than 500,000 people in the United States (mostly women). The disease is
highly heterogeneous, affecting a wide range of organs & tissue systems.
It is estimated that as many as 60% of all SLE patients have clinical LN
requiring treatment. Unlike SLE, LN has straightforward disease outcomes
where an early response correlates with long-term outcomes, measured by
proteinuria. In patients with LN, renal damage results in proteinuria
and/or hematuria and a decrease in renal function as evidenced by
reduced estimated glomerular filtration rate (eGFR), and increased serum
creatinine levels. LN is debilitating and costly and if poorly
controlled, LN can lead to permanent and irreversible tissue damage
within the kidney, resulting in end-stage renal disease (ESRD), thus
making LN a serious and potentially life-threatening condition.
VP, Investor Relations